MiMedx Group, Inc. and Sanara MedTech Inc. have entered into a definitive merger agreement under which MiMedx will acquire all of the outstanding shares of Sanara in a cash and stock transaction valued at $35 per Sanara share with a total enterprise value of approximately $350 million.
Sanara is solely focused on developing and commercialising regenerative products for surgical markets. With technologies targeting multiple, large addressable markets and a compelling financial profile, Sanara has a track record of delivering double-digit revenue growth as it has built its surgical commercial presence.
This transaction would combine MiMedx’s high-growth, best-in-class surgical portfolio with Sanara’s innovative surgical technologies across collagen particulate, wound irrigation and bone fixation.
In addition to Sanara’s industry-leading CellerateRX surgical powder, Biasurge advanced surgical solution and additional soft tissue and musculoskeletal products, it is working towards a 2027 commercial launch of OsStic BioAdhesive Advanced Bone Fixation, a breakthrough device as designated by the US Food & Drug Administration.
This merger of MiMedx and Sanara is expected to result in a stronger long-term growth profile with significantly expanded addressable markets and positions the combined company as a leader in regenerative medicine solutions for the operating room.
Under the terms of the agreement, Sanara shareholders will receive $33 in cash and 0.4735 shares of MiMedx common stock for each share of Sanara common stock they own, which represents a value of $2 per share, calculated based on the average closing price of MiMedx common stock of $4.22 for the last five consecutive trading days through and including 28 July 2026.
